04 Apr, 13:39 - Indian

SENSEX 75460.71 (-1.09)

Nifty 50 22943.35 (-1.32)

Nifty Bank 51631.65 (0.07)

Nifty IT 33714.95 (-3.00)

Nifty Midcap 100 50679.7 (-2.84)

Nifty Next 50 61562.15 (-2.44)

Nifty Pharma 20508.1 (-4.27)

Nifty Smallcap 100 15718.2 (-3.31)

04 Apr, 13:39 - Global

NIKKEI 225 33780.58 (-2.75)

HANG SENG 22849.81 (-1.52)

S&P 5407.5 (-0.68)


Corporate News

You are Here : Home > News > Corporate News >

(31 Mar 2025, 10:19)

Sun Pharma Advanced Research Company submits IND application to USFDA

Ahead of Phase 1 clinical trial of SBO-154 for treatment of solid tumors


Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

“SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.” said Anil Raghavan, CEO of SPARC.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumors. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumors. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.

More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +